65,437 trials
Disorder of Bone Density and Structure, Unspecified
Primary: Change in Spine Bone Density (g/cm^2) — -0.00558 gm/cm^2 — p=0.40
Pregnancy · Postpartum Period · Sleep Disturbance
Primary: Maternal Sleep Quantity (Objective) — 6.1; 6.6 hours
Human Immunodeficiency Virus (HIV) · Vitamin D Deficiency · HIV Infections
Primary: Change in Endothelial Function — 0.29; 0.55 percent change in endothelial function
Multiple Sclerosis
Primary: Summary of Treatment Emergent Adverse Events (TEAE). — 176; 65; 102; 34 participants
Primary Insomnia · Secondary Insomnia
Primary: Change From Baseline in Average Nightly Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint — 30.16; 37.33; 50.63; 22.79 minutes
Transplant Rejection · Renal Transplantation
Primary: Maximum Observed Blood Concentration at Steady State (Cmax,ss) — 14.07 nanogram per milliliter (ng/mL)
Prostatic Hyperplasia
Primary: Number of Participants Who Experienced Progression of Disease — 589; 393; 280; 212 participants — p=0.002
Pain · Back Pain · Low Back Pain
Primary: Sum of Pain Intensity Difference (SPID) for Low Back Pain - Summary Statistics at 120 Hours (With Imputation) — 264.6; 264.0 Units on a scale — p=0.9703
Scleroderma
Primary: Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), or Adverse Events (AEs) — 0; 31; 7; 0 Participants
Prostatic Hyperplasia
Primary: Number of Participants by Treatment Cohort With and Without a Benign Prostatic Hypertrophy (BPH) Diagnosis — 122307; 9456; 3293; 3674 participants
Glioblastoma Multiforme · Glioma
Primary: Number of Participants Progression Free at 6 Months With Malignant Gliomas — 24 participants
Moderate to Severe Pain Due to Diabetic Polyneuropathy
Primary: Short Form McGill Pain Score. — 49.56; 47.65 units on a scale
Hepatitis B Virus
Primary: Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12. — -3.852; -4.175; -4.374 log10 copies/mL
Hematologic Malignancies
Primary: Maximum Tolerated Dose (MTD) — 11.2 mg/kg
Primary Dysmenorrhea
Primary: Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain — -4.6; -4.2 Days